Clinicopathological characteristics and genomic profile of primary sinonasal tract diffuse large B cell lymphoma (<scp>DLBCL</scp>) reveals gain at 1q31 and <scp>RGS</scp>1 encoding protein; high <scp>RGS</scp>1 immunohistochemical expression associates with poor overall survival in <scp>DLBCL</scp> not otherwise specified (<scp>NOS</scp>)

Carreras, Joaquim; Kikuti, Yara Yukie; Beà, Sı́lvia; Miyaoka, Masashi; Hiraiwa, Shinichiro; Ikoma, Haruka; Nagao, Ryoko; Tomita, Sakura; Martín‐Garcia, David; Salaverría, Itziar; Sato, Ai; Ichiki, Akifumi; Roncador, Giovanna; Garcı́a, Juan F.; Ando, Kiyoshi; Campo, Elı́as; Nakamura, Naoya

doi:10.1111/his.13106

Cited by 47 publications

(59 citation statements)

References 72 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Consistently, a Korean study showed only one CNS recurrence among 80 cases of in sinonasal DLBCL (with 30% rate of intrathecal prophylaxis), and no difference in survival with RT, confirming that in the rituximab era neither RT nor routine intrathecal therapy are necessary (Table 2) [69]. Little is known about specific molecular features of DLBCL of the head and neck, except that 80% are non-GCB, with frequent gain of 1q31 (containing RGS1 , 55%) and loss of 9p21.3 (containing CDKN2A , 64%) [70]. Extranodal head/neck location was associated with a better prognosis than nodal DLBCL in population-derived data, but not in clinicopathologic series [2, 14, 4, 68].…”

Section: Prognosis Of Extranodal Dlbcl Arising From Specific Anatomicmentioning

confidence: 95%

Extranodal Diffuse Large B Cell Lymphoma: Molecular Features, Prognosis, and Risk of Central Nervous System Recurrence

Ollila

Olszewski

2018

Curr. Treat. Options in Oncol.

115

107

View full text Add to dashboard Cite

Diffuse large B cell lymphoma (DLBCL) arises from extranodal organs in about 30% of cases. Its prognosis and risk of recurrence in the central nervous system (CNS) vary according to the primary site of origin. Recent studies begin to clarify these differences using molecular classification. Testicular, breast, and uterine DLBCL (as well as possibly primary cutaneous DLBCL, leg-type) share a high prevalence of the non-germinal center B cell (non-GCB) phenotype and the MYD88/CD79B-mutated (MCD) genotype. These biologic features, which resemble primary CNS lymphoma, may underlie their stage-independent propensity for CNS involvement. Management of these lymphomas should involve CNS prophylaxis, preferably using systemic high-dose methotrexate to prevent intraparenchymal recurrence. Involvement of the kidneys, adrenal glands, ovary, bone marrow, lung, or pleura usually indicates disseminated disease, conferring worse prognosis. Involvement of these sites is often associated with high CNS-International Prognostic Index (IPI), concurrent MYC and BCL2 or BCL6 rearrangements, or intravascular lymphoma-risk factors warranting CNS prophylaxis. In contrast, craniofacial, thyroid, localized bone, or gastric lymphomas have a variable prevalence of the non-GCB phenotype and lack MYD88 mutations. Their outcomes with standard immunochemotherapy are excellent, and the risk of CNS recurrence is low. We recommend individualized consideration of CNS prophylaxis based on the CNS-IPI score and anatomical proximity in cases of epidural, orbital, or skull involvement. Rituximab-containing immunochemotherapy is a standard approach for all extranodal DLBCLs. Surgery is no longer required for any primary site, but routine consolidative radiation therapy is recommended for testicular lymphoma. Radiation therapy also appears to be associated with better progression-free survival in primary bone DLBCL. Future studies should better distinguish primary from secondary sites of extranodal involvement, and investigate the association of newly identified genotypes with the risk of CNS or systemic recurrence.

show abstract

Section: Prognosis Of Extranodal Dlbcl Arising From Specific Anatomicmentioning

confidence: 95%

Extranodal Diffuse Large B Cell Lymphoma: Molecular Features, Prognosis, and Risk of Central Nervous System Recurrence

Ollila

Olszewski

2018

Curr. Treat. Options in Oncol.

115

107

View full text Add to dashboard Cite

show abstract

“…46,47 Immunohistochemistry Immunohistochemical analysis was performed essentially as described previously. A skin sample from a healthy donor and lymph nodes showing reactive hyperplasia were used as a positive and negative control of IL-34 signal, respectively.…”

Section: Tissue Samplesmentioning

confidence: 99%

Expression of IL‐34 correlates with macrophage infiltration and prognosis of diffuse large B‐cell lymphoma

et al. 2019

Self Cite

View full text Add to dashboard Cite

Objectives Infiltration of macrophages through the tyrosine kinase receptor CSF1R is a poor prognosis factor in various solid tumors. Indeed, these tumors produce CSF1R ligand, macrophage colony‐stimulating factor (M‐CSF) or interleukin‐34 (IL‐34). However, the significance of these cytokines, particularly, the newly discovered IL‐34 in haematological malignancies, is not fully understood. We therefore analysed the role of IL‐34 in diffuse large B‐cell lymphoma (DLBCL), the most common subtype of malignant lymphoma. Methods We analysed formalin‐fixed paraffin‐embedded lymphoma tissues of 135 DLBCL patients for the expression of IL‐34 and the number of macrophages, and the survival of these patients. The expression of IL‐34 in DLBCL cell lines and the activity of IL‐34 to induce the migration of monocytic cells were also characterised. Results Several lymphoma tissues showed a clear IL‐34 signal, and such signal was detectable in 36% of patients. DLBCL cell lines also expressed IL‐34. Interestingly, the percentage of IL‐34+ patients in the activated B‐cell subtype was significantly higher than that in the germinal centre B‐cell subtype. More interestingly, IL‐34+ patients showed shorter survival periods and higher number of macrophages in lymphoma tissues. The recruitment of monocytes is likely the first step for the higher macrophage density in the IL‐34+ lymphoma tissues. Indeed, IL‐34 induced the migration of monocytic cells. Conclusion Our results raise the possibility that IL‐34 in lymphoma tissues of DLBCL patients recruits monocytes, leading to the higher number of macrophages in the tissues and poor prognosis of patients. IL‐34 may be an additional therapeutic target of DLBCL.

show abstract

“…Immunohistochemistry (IHC) staining was performed in an automated system according to the manufacturer's instructions [Leica Bond‐Max and Bond Polymer Refine Detection, DS9800. Novocastra (NV), Leica Microsystems K.K., Tokyo, Japan] . In summary, the staining process consisted on dewax, hydration, antigen retrieval, primary antibody, peroxidase block, postprimary reagent, HRP‐polymer, DAB and hematoxylin steps.…”

Section: Methodsmentioning

confidence: 99%

“…Novocastra (NV), Leica Microsystems K.K., Tokyo, Japan]. 18,19 In summary, the staining process consisted on dewax, hydration, antigen retrieval, primary antibody, peroxidase block, postprimary reagent, HRP-polymer, DAB and hematoxylin steps. Antigen retrieval consisted on Bond ER2 solution for 20 minutes in all the antibodies except for TNFRSF14, CD16 and PTX3 that used Bond ER1 solution.…”

Section: Histologic Disease Activity Assessmentmentioning

confidence: 99%

Prediction of steroid demand in the treatment of patients with ulcerative colitis by immunohistochemical analysis of the mucosal microenvironment and immune checkpoint: role of macrophages and regulatory markers in disease severity

Tsuda

Carreras

Kikuti

et al. 2019

Pathology International

Self Cite

View full text Add to dashboard Cite

We aimed to characterize the mucosal immune microenvironment and immune checkpoint of Ulcerative colitis (UC) by immunohistochemistry with correlation to prognosis: requirement of second‐line steroid‐therapy within the 2‐years after diagnosis (SR). A series of 72 cases included 56 UC, 43 non‐SR (with first‐line treatment 5‐ASA) and 13 SR, 11 infectious colitis and 5 normal colonic biopsies. Normal mucosa was characterized by low infiltrates but high BTLA and TNFRSF14. Compared to normal, UC had increased pan‐immune‐markers of CD3, CD8, FOXP3, PD‐1, CD68, CD16, CD163, PTX3 and CD11C but had decreased BTLA (P < 0.05); by GSEA analysis comparable results were found in an independent UC gene‐expression‐data set (GSE38713). Compared to infectious, UC had higher CD4, CD8, PTX3 and CD11C but lower BTLA (P < 0.05). Compared to non‐SR, SR had lower FOXP3 + Tregs (Odds‐Ratio = 0.114, P = 0.002), PD‐1 (OR = 0.176, P = 0.002) and CD163/CD68 M2‐ratio (OR, 0.019, P = 0.019) but higher CD68 + pan‐macrophages (OR = 6.034, P = 0.002). Higher Baron endoscopic and Geboes histologic disease activity scores also correlated with SR. In summary, UC was characterized by increased pan‐immune‐markers, normal TNFRSF14 and low BTLA. SR had increased CD68 + pan‐macrophages but lower immune inhibitors of FOXP3 + Tregs, PD‐1 and CD163/CD68 M2‐macrophage ratio. In conclusion, alterations of the immune homeostasis mechanisms are relevant in the UC pathogenesis and steroid‐requiring situation.

show abstract

Clinicopathological characteristics and genomic profile of primary sinonasal tract diffuse large B cell lymphoma (DLBCL) reveals gain at 1q31 and RGS1 encoding protein; high RGS1 immunohistochemical expression associates with poor overall survival in DLBCL not otherwise specified (NOS)

Abstract: DLBCL has a characteristic genomic profile. High RGS1 IHC expression associates with poor overall survival in DLBCL .

Cited by 47 publications

References 72 publications

Extranodal Diffuse Large B Cell Lymphoma: Molecular Features, Prognosis, and Risk of Central Nervous System Recurrence

Extranodal Diffuse Large B Cell Lymphoma: Molecular Features, Prognosis, and Risk of Central Nervous System Recurrence

Expression of IL‐34 correlates with macrophage infiltration and prognosis of diffuse large B‐cell lymphoma

Prediction of steroid demand in the treatment of patients with ulcerative colitis by immunohistochemical analysis of the mucosal microenvironment and immune checkpoint: role of macrophages and regulatory markers in disease severity

Contact Info

Product

Resources

About